8/20/2009 9:30 AM

Establishment of a new plant for biopharmaceutical manufacturing in Strängnäs in August 2009. After an extensive evaluation of ten competing sites, Sweden won the US$150 million investment of the 30,000 sqm manufacturing plant. The motive for Sweden was the long experience and great know-how in biopharmaceutical manufacturing and availability of a well-educated workforce.

Type of investment: Greenfield

Website: www.pfizer.com